$AILE
iLearningEngines Inc

2022 Q1 Form 10-Q Financial Statement

#000114036122019373 Filed on May 16, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $438.9K $942.5K
YoY Change -53.44%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $438.9K $942.5K
YoY Change -53.44%
Operating Profit -$438.9K -$942.5K
YoY Change -53.44%
Interest Expense $25.63K $1.890K
YoY Change 1256.08%
% of Operating Profit
Other Income/Expense, Net $6.361M $2.573M
YoY Change 147.19%
Pretax Income $5.922M $1.631M
YoY Change 263.16%
Income Tax $0.00 $0.00
% Of Pretax Income 0.0% 0.0%
Net Earnings $5.922M $1.631M
YoY Change 263.16%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share $164.8K $45.37K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $122.3K $871.5K
YoY Change -85.96%
Cash & Equivalents $122.3K $871.5K
Short-Term Investments
Other Short-Term Assets $413.0K $1.021M
YoY Change -59.55%
Inventory
Prepaid Expenses $1.021M
Receivables
Other Receivables
Total Short-Term Assets $535.3K $1.892M
YoY Change -71.71%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $287.5M $287.5M
YoY Change 0.01%
Other Assets $0.00
YoY Change
Total Long-Term Assets $287.5M $287.5M
YoY Change 0.01%
TOTAL ASSETS
Total Short-Term Assets $535.3K $1.892M
Total Long-Term Assets $287.5M $287.5M
Total Assets $288.1M $289.4M
YoY Change -0.46%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.149M $126.9K
YoY Change 805.44%
Accrued Expenses $0.00
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $950.0K $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.099M $126.9K
YoY Change 1553.89%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $15.72M $28.16M
YoY Change -44.19%
Total Long-Term Liabilities $15.72M $28.16M
YoY Change -44.19%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.099M $126.9K
Total Long-Term Liabilities $15.72M $28.16M
Total Liabilities $17.82M $28.29M
YoY Change -37.01%
SHAREHOLDERS EQUITY
Retained Earnings -$28.79M
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$17.26M -$26.40M
YoY Change
Total Liabilities & Shareholders Equity $288.1M $289.4M
YoY Change -0.46%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income $5.922M $1.631M
YoY Change 263.16%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$365.9K -$1.078M
YoY Change -66.05%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $25.50K -$287.5M
YoY Change -100.01%
Cash From Investing Activities $25.50K -$287.5M
YoY Change -100.01%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 200.0K 289.4M
YoY Change -99.93%
NET CHANGE
Cash From Operating Activities -365.9K -1.078M
Cash From Investing Activities 25.50K -287.5M
Cash From Financing Activities 200.0K 289.4M
Net Change In Cash -140.4K 849.6K
YoY Change -116.52%
FREE CASH FLOW
Cash From Operating Activities -$365.9K -$1.078M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
566-5966
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001835972
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-835972
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
true
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
ARROWROOT ACQUISITION CORP.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-3961600
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
4553 Glencoe Ave, Suite 200
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Marina Del Rey
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
90292
CY2022Q1 dei City Area Code
CityAreaCode
310
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
438862
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
942521
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-438862
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-942521
CY2022Q1 us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
6335000
CY2021Q1 us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
2571250
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
25629
CY2021Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
1891
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
1630620
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
6360629
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2573141
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
5921767
CY2021Q1 arrw Redeemable Ordinary Shares Accretion To Redemption Value
RedeemableOrdinarySharesAccretionToRedemptionValue
28713942
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
660000
CY2022Q1 arrw Working Capital
WorkingCapital
287523763
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold; font-variant: normal; text-transform: none;">Use of Estimates</div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">The preparation of the condensed financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenues and expenses during the reporting periods.<br/> </span> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant accounting estimates included in these financial statements is the</span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> determination of the fair value of the warrant liabilities. Such estimates may be subject to change as more current information becomes available and accordingly, the actual results could differ significantly from those estimates. </span></div>
CY2022Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2021Q1 arrw Deferred Underwriter Fee Per Unit
DeferredUnderwriterFeePerUnit
0.35
CY2021Q1 arrw Deferred Underwriting Commissions
DeferredUnderwritingCommissions
10062500
CY2021Q1 us-gaap Deferred Offering Costs
DeferredOfferingCosts
16392714
CY2021Q1 arrw Transaction Costs Allocated To Warrant Liabilities
TransactionCostsAllocatedToWarrantLiabilities
760022
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.21
CY2022Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022Q1 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2021Q1 arrw Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
22625000
CY2022Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q1 arrw Stock Conversion Ratio
StockConversionRatio
1
CY2022Q1 arrw Stock Conversion As Converted Percentage
StockConversionAsConvertedPercentage
0.20
CY2022Q1 arrw Stock Conversion Ratio
StockConversionRatio
1
CY2022Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold; font-variant: normal; text-transform: none;">Concentration of Credit Risk</div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times may exceed the Federal Deposit Insurance Corporation coverage limit of $250,000. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such account.</div>
CY2021Q1 arrw Number Of Director Nominees
NumberOfDirectorNominees
3
CY2022Q1 arrw Period To Exercise Warrants After Business Combination
PeriodToExerciseWarrantsAfterBusinessCombination
P30D
CY2022Q1 arrw Period To Exercise Warrants After Closing Of Initial Public Offering
PeriodToExerciseWarrantsAfterClosingOfInitialPublicOffering
P12M
CY2022Q1 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
CY2022Q1 arrw Period To File Registration Statement After Initial Business Combination
PeriodToFileRegistrationStatementAfterInitialBusinessCombination
P15D
CY2022Q1 arrw Period For Registration Statement To Become Effective
PeriodForRegistrationStatementToBecomeEffective
P60D
CY2022Q1 arrw Class Of Warrant Or Right Redemption Price
ClassOfWarrantOrRightRedemptionPrice
0.01
CY2022Q1 arrw Notice Period To Redeem Warrants
NoticePeriodToRedeemWarrants
P30D
CY2022Q1 arrw Threshold Trading Days
ThresholdTradingDays
P20D
CY2022Q1 arrw Threshold Consecutive Trading Days
ThresholdConsecutiveTradingDays
P30D
CY2022Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
25500

Files In Submission

Name View Source Status
0001140361-22-019373-index-headers.html Edgar Link pending
0001140361-22-019373-index.html Edgar Link pending
0001140361-22-019373.txt Edgar Link pending
0001140361-22-019373-xbrl.zip Edgar Link pending
arrw-20220331.xsd Edgar Link pending
arrw-20220331_cal.xml Edgar Link unprocessable
arrw-20220331_def.xml Edgar Link unprocessable
arrw-20220331_lab.xml Edgar Link unprocessable
arrw-20220331_pre.xml Edgar Link unprocessable
brhc10037533_10q.htm Edgar Link pending
brhc10037533_10q_htm.xml Edgar Link completed
brhc10037533_ex31-1.htm Edgar Link pending
brhc10037533_ex31-2.htm Edgar Link pending
brhc10037533_ex32-1.htm Edgar Link pending
brhc10037533_ex32-2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending